Remove Assay Development Remove Disease Remove Small Molecule
article thumbnail

RNA processing in health and disease: challenges and opportunities of the field

Drug Target Review

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing.

RNA 96
article thumbnail

New image-based cellular profiling tool peers deeply into metabolic biology

Broad Institute

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Fat cells stained yellow to show the actin cytoskeleton, plasma membrane, and Golgi apparatus. Credit: Phil Kubitz, Claussnitzer lab Fat cells stained blue to show nuclei.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. There, I supported AI-enabled DD efforts in their small molecule portfolio.

article thumbnail

Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

Sygnature Discovery

The biotech will continue partnering with Sygnature to drive its novel, genetically validated cardiovascular disease project pipeline. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more.